摘要
目的观察大黄虫丸在治疗慢乙肝中抗肝纤维化的临床疗效。方法对45例常规护肝治疗的慢乙肝患者加用大黄虫丸,同期45例常规护肝治疗的慢乙肝患者作对照。结果两组护肝疗效和转归相同,无显著性差异(P>0.05);另观察到血清肝纤维化标志物(HA,LN,PⅢP,Ⅳ-C,CG)的改善、大黄虫丸组均显优于对照组(P<0.05)。结论大黄虫丸对慢乙肝抗肝纤维化有确切疗效;其抗肝纤维化的疗效与大黄蜃虫丸活血破瘀、软坚散结、清热解毒及显著抑制基质金属蛋白酶抑制剂(TIMP)直接相关,与常规护肝药物无直接关系。
Objective To evaluate the clinical curative effect of Rhubarb ＆ eupolyphage sinensis pills （ RESP, Dahuang Zhechoug Wan） on anti - fibrosis in liver during the treatment with chronic hepatitis B. Methods Rhubarb ＆ eupolyphage sinensis pills （RESP） were added during the conventional treatment with liver protection in 45 patients with chronic hepatitis B, while the conventional treatment with liver protection along in another 45cases with chronic hepatitis B was compared. Results There was analogous curative effect with liver protection and prognosis , no significant discrepancy between the two groups（ P 〉 0. 05 ）. The serum liver fibrosis markers, including hyaluronic acid（HA）; laminin（LN） ; procollagen Ⅲ N - terminal peptide（PIIIP） ; type IV collage（Ⅳ- C）; choly- 1-glycine（CG） were more obviously improved in RESP group than those in control group（P 〈 0.05）. Conclusion The curative effect of RESP on anti-fibrosis was obvious, which was directly related to improving the blood circulation , dispersing blood staganation, doing away with the extravased blood , diving witness-heatevil and the virus and obviously inhibiting tissue inhibitor of metalloproteinase, and not to the conventional liver-protective therapy.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2006年第5期808-809,共2页
Lishizhen Medicine and Materia Medica Research
关键词
慢性乙型肝炎
肝纤维化
大黄[庶虫]虫丸
透明质酸
层粘蛋白
Ⅲ型前肢原氨基端肽
Ⅳ型胶原
甘氨胆酸
组织金属蛋白酶抑制剂
Chronic hepatitis B （CHB）
Liver fibrosis
Dahuang Zhechoug Wan ）
Hyaluronic acid （HA）
Laminin（LN）
Procollagen Ⅲ N - terminal peptide （ PⅢP）
Type Ⅳ collage（Ⅳ-C）
Choly-l-glycine（CG）
Tissue inhibitor of metalloproteinase （ TIMP ）
